Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20435020 | 1.00 | DNMT1 (0.41) | DNMT1DNMT3BADORA3ADORA2BADORA1 | |
| SCHEMBL26292123 | 0.93 | ADORA3 (0.43) | DNMT1DNMT3BADORA3ADORA2BADORA1 | |
| SCHEMBL24505731 | 0.89 | ADORA3 (0.48) | DNMT1DNMT3BADORA3ADORA2BADORA1 | |
| SCHEMBL20435023 | 0.87 | SLC29A1 (0.48) | DNMT1DNMT3BADORA3SLC29A1CYP3A4 | |
| SCHEMBL20435022 | 0.87 | SLC29A1 (0.48) | DNMT1DNMT3BADORA3SLC29A1CYP3A4 | |
| SCHEMBL26292122 | 0.87 | SLC29A1 (0.48) | DNMT1DNMT3BADORA3SLC29A1CYP3A4 | |
| SCHEMBL24505817 | 0.85 | — | — | |
| SCHEMBL24505811 | 0.83 | ADORA3 (0.44) | ADORA3ADORA2BADORA1SLC29A1TSHR | |
| SCHEMBL20434958 | 0.83 | ADORA3 (0.44) | ADORA3ADORA2BADORA1SLC29A1TSHR | |
| SCHEMBL20435000 | 0.83 | ADORA3 (0.45) | ADORA3ADORA2BADORA1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753432-B2 | Compound with analgesic effect for use in prevention and treatment of pain | ACADEMIA SINICA (TW) | 2023-09-12 | — | — | US | disclosed |
| EP-3573996-B1 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | ACADEMIA SINICA (TW) | 2022-06-15 | — | — | EP | disclosed |
| WO-2018140734-A1 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | ACADEMIA SINICA (TW) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753432-B2 | Compound with analgesic effect for use in prevention and treatment of pain | ADORA2B, ADORA1, ADORA3 | DNMT1 962/4885DNMT3B 1007/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.